BioNTech SE
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
BioNTech co-founders Uğur Şahin and Özlem Türeci named their new pharmaceutical company 'Arife,' focusing on next-gen medicines, particularly mRNA-based. Arife will be based in Mainz, Germany, and conduct R&D, manufacturing, and marketing. Şahin and Türeci plan to leave BioNTech by 2026 but remain shareholders. BioNTech's next CEO, Guido Oelkers, will start by Feb. 1, 2027.
BioNTech's stock has fallen 63.3% over 5 years, raising questions about its valuation. Recent Phase 3 lung cancer trial data showed promising results, potentially boosting long-term revenue expectations. The company trades at 8.3x P/S, lower than peers. Analysts are divided on whether the oncology pipeline justifies the current valuation, with bulls seeing 16% undervaluation and bears citing 18% overvaluation due to declining COVID-19 vaccine demand.
Pfizer (PFE) and BioNTech (BNTX) received FDA approval for their updated COVID-19 vaccine, COMIRNATY XFG, targeting the XFG variant. The approval secures their position in seasonal COVID-19 immunizations, providing a stable revenue stream. For Pfizer, this supports cash flow and pipeline investments, while for BioNTech, it validates its mRNA platform and maintains market share. Both companies face risks from potential demand declines and market contraction.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning BNTX (BioNTech SE). Coverage has skewed bearish: 1 bullish, 2 neutral, and 3 bearish.
Recent BNTX coverage spans technology, insider activity and financial news.
In the last 30 days, BNTX insiders filed 15 SEC Form 4 transactions — no purchases and 15 sales ($51.2M). The most active reporter was Sahin Ugur, Chief Executive Officer, with 15 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Potential dilution of focus and shareholder attention from BioNTech; possible future competition.
Positive trial data could lift BioNTech's valuation and drive short-term buying pressure.
Approval defends liquidity but highlights reliance on a contracting COVID market.
The insider sale may signal reduced confidence or liquidity need, potentially pressuring the stock short‑term.
The trial halt may pressure the stock, while early lung cancer results could provide upside if confirmed.
AlphAI scores every news story that mentions BNTX with an AI model for sentiment and relevance, and aggregates insider trades from BioNTech SE's SEC EDGAR Form 4 filings. Figures refresh continuously.
BioNTech co-founders Uğur Şahin and Özlem Türeci named their new pharmaceutical company 'Arife,' focusing on next-gen medicines, particularly mRNA-based. Arife will be based in Mainz, Germany, and conduct R&D, manufacturing, and marketing. Şahin and Türeci plan to leave BioNTech by 2026 but remain shareholders. BioNTech's next CEO, Guido Oelkers, will start by Feb. 1, 2027.
1 min readBioNTech's stock has fallen 63.3% over 5 years, raising questions about its valuation. Recent Phase 3 lung cancer trial data showed promising results, potentially boosting long-term revenue expectations. The company trades at 8.3x P/S, lower than peers. Analysts are divided on whether the oncology pipeline justifies the current valuation, with bulls seeing 16% undervaluation and bears citing 18% overvaluation due to declining COVID-19 vaccine demand.
2 min readPfizer (PFE) and BioNTech (BNTX) received FDA approval for their updated COVID-19 vaccine, COMIRNATY XFG, targeting the XFG variant. The approval secures their position in seasonal COVID-19 immunizations, providing a stable revenue stream. For Pfizer, this supports cash flow and pipeline investments, while for BioNTech, it validates its mRNA platform and maintains market share. Both companies face risks from potential demand declines and market contraction.
2 min readSahin Ugur (Chief Executive Officer) sold 69,000 shares of BioNTech SE (BNTX) at an average of $99.17 ($98.99–$99.40, $6.84M total) across 2 trades over 2026-09-23 to 2026-09-24 under a Rule 10b5-1 trading plan.
1 min readBioNTech (BNTX) reported mixed clinical trial results. Its colorectal cancer vaccine, autogene cevumeran, failed in a Phase 2 trial, causing a 10% stock drop. However, its lung cancer treatment, Gotistobart, showed promising early Phase 3 results with a median overall survival of 18.5 months. The company's future depends on upcoming clinical trials, including BNT113 for head and neck cancer, which has received FDA Fast Track designation.
2 min readBioNTech CEO Ugur Sahin sold 79,000 shares under a pre-arranged trading plan, retaining a large indirect stake via Medine GmbH. The sales occurred on September 21-22, 2026, at average prices of $99.25 per share, totaling $7.86 million. Sahin indirectly holds 39.2 million shares through Medine GmbH, with 106,721 shares held in trust.
1 min readSahin Ugur (Chief Executive Officer) sold 79,000 shares of BioNTech SE (BNTX) at an average of $99.50 ($97.81–$100.72, $7.86M total) across 2 trades over 2026-09-21 to 2026-09-22 under a Rule 10b5-1 trading plan.
1 min readBMO Capital Markets downgraded BioNTech (BNTX) from 'outperform' to 'market perform', lowering its price target from $128 to $105. The downgrade follows a canceled Phase 2 trial for a cancer vaccine and reduced revenue guidance. BioNTech's market cap is around $24B, with $19B in cash and investments, and it has 25+ ongoing cancer therapy trials.
2 min readModerna's shares rose 9% after its Phase 3 melanoma study was selected for a Presidential Symposium at the European Society for Medical Oncology congress. Merck and BioNTech also saw gains. The stock is trading at $167.90. No new data was released, but the high-profile presentation is seen as a positive signal.
2 min readA BioNTech insider sold shares worth $6,239,071, according to a recent SEC filing. The company's stock is currently trading at $96.06 on the Nasdaq, with a 5-day change of -2.64%.
1 min read
